Charles L. Pope

Chairman of the Board

Charles Pope serves as Chairman of the Oragenics Board of Directors, bringing a depth of financial governance and regulatory expertise shaped by decades of work across industries and public companies. 

He has served as CFO for five companies across a range of sectors, including TRxADE HEALTH (Scienture Holdings). Prior to his executive leadership roles, Mr. Pope was a Partner in the Audit and Financial Advisory Consulting Divisions and the Accounting and SEC Directorate at PricewaterhouseCoopers — one of the world’s premier professional services firms. His regulatory and audit experience at PwC provides the board with a direct connection to the standards and practices required of a NYSE-listed company. 

As Chairman, he provides financial oversight, strategic guidance, and accountability to Oragenics’ management team as the company advances through a critical phase of clinical and capital markets activity. 

Alan Dunton, M.D.

Director

Dr. Dunton has served as a Director of Oragenics, Inc. since April 2010. He is the principal owner of Danerius, LLC, a biotechnology consulting company which he founded in 2006. In addition to Oragenics, he is currently a Director of the public biotechnology company, Palatin, Inc. (AMEX: PTN), CorMedix (NASDAQ: CRMD) and Recce Pharmaceuticals (ASX: RCE). Dr. Dunton previously served as a Director of Sancilio and Company, MediciNova, Regeneus, and Targacept, Inc. Dr. Dunton is also a member of the Board of Director of CorMedix, Inc. (CRMD), a publicly traded biotechnology company in Berkeley Heights, New Jersey since March 2019. Dr. Dunton has held significant senior positions in major pharmaceutical companies. Most recent was from November 2015 through March 2018 as the Senior Vice President of Research, Development and Regulatory Affairs of Purdue Pharma L.P., a private pharmaceutical company. From January 2007 until March 2009, Dr. Dunton served as President and Chief Executive Officer of Panacos Pharmaceuticals, Inc. Dr. Dunton was the non-Executive Chairman and Director of EpiCept, Inc. (OTC MKTS: EPCT) a public biotechnology company developing products for cancer, pain and inflammatory conditions. In 2005, Dr. Dunton served as the Non-Executive Chairman of the Board of Directors of ActivBiotics, Inc., a private biopharmaceutical company. Previously, Dr. Dunton was the President and Chief Executive Officer of Metaphore Pharmaceuticals, Inc. from 2003 until 2006, when it merged with ActivBiotics. From 2004 until 2005, Dr. Dunton served as a member of the board of directors of Vicuron Pharmaceuticals until it was acquired by Pfizer, Inc. In 2002, Dr. Dunton served as President, Chief Operating Officer and a director of Emisphere Technologies, Inc., a biopharmaceutical company. From 1994 to 2001, Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson. From 1999 to 2001, Dr. Dunton was President and Managing Director of The Janssen Research Foundation, a Johnson & Johnson company. From 1998 to 1999, Dr. Dunton served as Group Vice President of Global Clinical Research and Development of Janssen. Prior to joining Janssen, Dr. Dunton was Vice President of Global Clinical Research and Development at the R.W. Johnson Pharmaceutical Research Institute, also a Johnson & Johnson company. Prior to joining Johnson & Johnson, Dr. Dunton held positions in clinical research and development at Syntex Corporation, CIBA-GEIGY Corporation and Hoffmann La Roche Inc. Dr. Dunton holds a MD degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center.

Robert Koski

Director

Mr. Koski has served as a Director since June 2009. Mr. Koski has practiced as an attorney with the Koski Firm, a sole proprietorship located in Atlanta, Georgia since 1992, where his practice includes litigation and tax law. Mr. Koski has also served as a partner in the Koski Family Limited Partnership, which beneficially owns an interest in the Company, and as a director of the Koski Family Foundation since December 1996. Mr. Koski holds a B.A. degree in Philosophy and English from Colgate University, a JD from Emory School of Law and an LLM degree in Taxation and Litigation from Emory University.

Frederick W. Telling

Director

Dr. Telling has served as Director since 2010 and was elected Chairman of the Board of Directors on February 4, 2011 and was appointed as Executive Chairman on May 2, 2021 following the resignation of Dr. Joslyn, the Company’s former President and Chief Executive Officer. Dr. Telling also serves on the boards of various civic and non-profit organizations. Dr. Telling retired from Pfizer Inc. in 2007 after 30 years of service as their Corporate Vice President and Vice President of Corporate Strategic Planning and Policy. He focused on product licensing, mergers and acquisitions, and global health policy. Telling holds a B.A. in History and Economics from Hamilton College, an M.A. in Industrial and Labor Relations, and a PhD in Economics and Public Policy from Cornell University.

John Gandolfo

Director

Mr. Gandolfo has more than 30 years of experience as a Chief Financial Officer (CFO) of multiple rapidly growing private and publicly held companies with a primary focus in the life sciences, healthcare and medical device areas. Mr. Gandolfo has had direct responsibility over all financial and treasury functions including capital raising and mergers and acquisitions. Mr. Gandolfo currently serves as CFO of Eyenovia, Inc., (EYEN) a late-stage ophthalmic biopharmaceutical company since January 2018. Prior to this, Mr. Gandolfo was CFO of Xtant Medical Holdings, Inc., a biologics company, from July 2010 through September 2017. Prior to this, he served as the CFO for Progenitor Cell Therapy LLC from January 2009 to June 2010 and, before that, as CFO of Power Medical Interventions, Inc. from January 2007 to January 2009. Mr. Gandolfo currently serves on the Board of Directors of Electrocore, Inc. (ECOR) and previously served on the Board of Directors and was chair of the Audit Committee of Odyssey Health, Inc. f/k/a Odyssey Group International, Inc., (ODDY) from 2019 until 2023. Oragenics announced the signing of an asset purchase agreement with Odyssey Health on October 6, 2023.

Mr. Gandolfo is currently a member of the Board of Directors of Electrocore, Inc. (ECOR) and is chair of the Compensation Committee and sits on their audit committee. Mr. Gandolfo received his B.A. degree in Business Administration from Rutgers University.

Natasha Giordano

Board Member

Natasha Giordano brings to the Oragenics board the perspective of a public company CEO — someone who has led organizations through the scrutiny, stakeholder management, and governance demands of publicly traded life sciences environments. 

A strategic advisor known for her direct, accountability-driven approach, she joined the board to help accelerate the company’s transition from clinical-stage operations to a market-ready, investor-credible organization. She has been an active voice in shaping Oragenics’ strategic priorities, including its pipeline narrative, capital markets positioning, and external scientific visibility.